Paper20172016
Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
Decot V and 6 others. Exp Hematol, 2010. Cited by 56 papers, by iCite.
Cite this record
ConductScience Library. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Papers, record 20172016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20172016
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy, Adoptive | Major topic |
| Interleukin-15 | Major topic |
| Interleukin-2 | Major topic |
| Interleukin-7 | Major topic |
| Killer Cells, Natural | Major topic |
| Leukemia | Major topic |
| NK Cell Lectin-Like Receptor Subfamily K | Major topic |
| Receptors, KIR2DL1 | Major topic |
| Receptors, KIR2DL2 | Major topic |
| Cell Division | |
| Cell Separation | |
| Cells, Cultured | |
| Cytotoxicity, Immunologic | |
| Flow Cytometry | |
| HLA Antigens | |
| Humans | |
| Immunophenotyping |
Source PubMed
Cited by36
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41128942 | Generation of the augmented IL-15-secreting anti-HER2 chimeric antigen receptor (CAR)-NK cells: an encouraging immunotherapeutic tool. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/41128942 | PubMed |
| 40707132 | Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40707132 | PubMed |
| 39286242 | Proliferation capability of natural killer cells upon cytokines stimulation correlated negatively with serum lactate dehydrogenase level in coronary artery disease patients. | Front Immunol | 2024 | https://conductscience.org/library/papers/39286242 | PubMed |
| 39133343 | Computational modeling study of IL-15-NGR peptide fusion protein: a targeted therapeutics for hepatocellular carcinoma. | AMB Express | 2024 | https://conductscience.org/library/papers/39133343 | PubMed |
| 37139599 | Maintenance therapy in acute myeloid leukemia: advances and controversies. | Haematologica | 2023 | https://conductscience.org/library/papers/37139599 | PubMed |
| 36060136 | Bioactivity of Exosomes Derived from Trained Natural Killer Cells versus Non-Trained One: More Functional and Antitumor Activity. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/36060136 | PubMed |
| 35639116 | Natural killer cells and acute myeloid leukemia: promises and challenges. | Cancer Immunol Immunother | 2022 | https://conductscience.org/library/papers/35639116 | PubMed |
| 35486482 | Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. | Blood Adv | 2022 | https://conductscience.org/library/papers/35486482 | PubMed |
| 35286691 | The Immunogenetics of Alopecia areata. | Adv Exp Med Biol | 2022 | https://conductscience.org/library/papers/35286691 | PubMed |
| 34835294 | The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/34835294 | PubMed |
| 33946954 | Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. | Cells | 2021 | https://conductscience.org/library/papers/33946954 | PubMed |
| 33287858 | Natural killer cell-based immunotherapy for acute myeloid leukemia. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/33287858 | PubMed |
| 32568180 | Anti-Relapse effects of donor natural killer cells and IL-2 gene modification on allogeneic hematopoietic stem cell transplantation in acute leukemia. | Cancer Biomark | 2020 | https://conductscience.org/library/papers/32568180 | PubMed |
| 32480431 | Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy. | J Leukoc Biol | 2020 | https://conductscience.org/library/papers/32480431 | PubMed |
| 30501078 | Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/30501078 | PubMed |
| 29948616 | IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients. | Pathol Oncol Res | 2020 | https://conductscience.org/library/papers/29948616 | PubMed |
| 29163501 | Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2. | Front Immunol | 2017 | https://conductscience.org/library/papers/29163501 | PubMed |
| 29019081 | Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15. | Immunol Res | 2017 | https://conductscience.org/library/papers/29019081 | PubMed |
| 28622272 | NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells. | J Immunother | 2017 | https://conductscience.org/library/papers/28622272 | PubMed |
| 27356741 | PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells. | Oncotarget | 2016 | https://conductscience.org/library/papers/27356741 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| IL15 | 3600 | PubTator's text mining | https://conductscience.org/library/genes/3600 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| IL7 | 3574 | PubTator's text mining | https://conductscience.org/library/genes/3574 | NCBI Gene |
| KIR2DL1 | 3802 | PubTator's text mining | https://conductscience.org/library/genes/3802 | NCBI Gene |
| KIR2DL2 | 3803 | PubTator's text mining | https://conductscience.org/library/genes/3803 | NCBI Gene |
| KLRK1 | 22914 | PubTator's text mining | https://conductscience.org/library/genes/22914 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20172016
GET https://conductscience.org/api/papers/v1/20172016/cited_by?page=2